Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years

Hely, Mariese A., Morris, John G.L., Reid, Wayne G.J., Trafficante, Robert·2005·Movement Disorders

DOI 10.1002/mds.20324

Cited by (1,000)

Items 601–700 of 1,000

Combined mGlu2 orthosteric stimulation and positive allosteric modulation alleviates l-DOPA-induced psychosis-like behaviours and dyskinesia in the parkinsonian marmoset
Stephen G. Nuara, Adjia Hamadjida, Cynthia Kwan, Dominique Bédard, Imane Frouni, Jim C. Gourdon, Philippe Huot · 2020 · Journal of Neural Transmission
Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset
Cynthia Kwan, Stephen G. Nuara, Jim C. Gourdon, Philippe Huot · 2021 · Naunyn-Schmiedeberg s Archives of Pharmacology
Cell Therapy for Parkinson's Disease: Only Young Onset Patients Allowed? Reflections about the Results of Recent Clinical Trials with Cell Therapy and the Progression of Parkinson's Disease
Gurutz Linazasoro · 2006 · Cell Transplantation
Effects of dietary factors on levodopa pharmacokinetics
Nélida Fernández, Juan Jose Garcia, M. José Diez, Ana M. Sahagún, Raquel Díez, Matilde Sierra · 2010 · Expert Opinion on Drug Metabolism & Toxicology
Do Tardive Dyskinesia and l-Dopa Induced Dyskinesia Share Common Genetic Risk Factors? An Exploratory Study
Lior Greenbaum, Stefano Goldwurm, Polina Zozulinsky, Tzuri Lifschytz, Oren S. Cohen, Gilad Yahalom, Roberto Cilia, Silvana Tesei, Rosanna Asselta, Rivka Inzelberg et al. · 2013 · Journal of Molecular Neuroscience
Multi-predictor modeling for predicting early Parkinson’s disease and non-motor symptoms progression
Kaixin Dou, Jiangnan Ma, Xue Zhang, Wanda Shi, Mingzhu Tao, Anmu Xie · 2022 · Frontiers in Aging Neuroscience
Elucidating distinct molecular signatures of Lewy body dementias
Joshua Harvey, Ehsan Pishva, Leonidas Chouliaras, Katie Lunnon · 2023 · Neurobiology of Disease
Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?
Daniella Rylander Ottosson, Emma L. Lane · 2016 · Frontiers in Cellular Neuroscience
Effects of Oral Levodopa on Balance in People with Idiopathic Parkinson’s Disease
Tim Leroy, Remco Johan Baggen, Nina Lefeber, Nolan Herssens, Patrick Santens, Miet De Letter, Leen Maes, Katie Bouche, Anke VAN BLADEL · 2022 · Journal of Parkinson s Disease
Non-motor symptoms in Indian patients with Parkinson’s disease
Aaron de Souza, Varun R. Pai Kakode, Zico D’Costa, Siddesh K. Bhonsle · 2015 · Basal Ganglia
Basal ganglia disorders
Marsha E. Melnick · 2013 · Elsevier eBooks
Current Therapeutic Strategies and Perspectives for Neuroprotection in Parkinson’s Disease
Mohan Krishna Ghanta, P Elango, Lakkakula VKS Bhaskar · 2020 · Current Pharmaceutical Design
Mastering nocturnal jigsaws in Parkinson’s disease: a dusk-to-dawn review of night-time symptoms
Roongroj Bhidayasiri, Jirada Sringean, Claudia Trenkwalder · 2020 · Journal of Neural Transmission
Informant Perceptions of the Cause of Activities of Daily Living Difficulties in Parkinson’s Disease
Jared F. Benge, Steve M. Balsis · 2016 · The Clinical Neuropsychologist
Sleep Disorders in Parkinson's Disease
Cynthia L. Comella · 2008 · Sleep Medicine Clinics
Cognitive decline in Parkinson disease
Linda Ann Hershey, Guerry M. Peavy · 2015 · Neurology
Predictive language comprehension in Parkinson’s disease
Katharine Aveni, Juweiriya Ahmed, Arielle Borovsky A, Ken McRae, Mary E. Jenkins, Katherine A. Sprengel, J. Alex Fraser, Joseph B. Orange, Thea Knowles, Angela Roberts · 2023 · PLoS ONE
Therapeutic singing-induced swallowing exercise for dysphagia in advanced-stage Parkinson’s disease
Myung Sun Yeo, Jihye Hwang, Hye Kyoung Lee, Soo Ji Kim, Sung‐Rae Cho · 2024 · Frontiers in Neurology
Precision Balance Assessment in Parkinson’s Disease: Utilizing Vision-Based 3D Pose Tracking for Pull Test Analysis
Nina Ellrich, Kasimir Niermeyer, Daniela K. Peto, Julian Decker, Urban M. Fietzek, Sabrina Katzdobler, Günter U. Höglinger, Klaus Jahn, Andreas Zwergal, Max Wuehr · 2024 · Sensors
Depressive Symptoms in Parkinson Disease: Degree of Association and Rate of Agreement of Clinician-Based and Self-Report Measures
Cynthia R. Cimino, Craig A. Siders, Theresa Zesiewicz · 2011 · Journal of Geriatric Psychiatry and Neurology
Treatments for Neurological Gait and Balance Disturbance: The Use of Noninvasive Electrical Brain Stimulation
Diego N. Kaski, Adolfo Miguel Bronstein · 2014 · Advances in Neuroscience
Dysphagia in Parkinson’s Disease
Emilia Michou, Christopher Kobylecki, Shaheen Hamdy · 2017 · Medical radiology
Distinctive Olfactory Pattern in Parkinson’s Disease and Non-Neurodegenerative Causes of Hyposmia
Ane Miren Crespo Cuevas, Lourdes Ispierto, Dolores Vilas, Anna Maria Planas, Albert Planas, Irina Isern, Josep Anton Sánchez, Josep de Haro, Ramiro Álvarez · 2018 · Neurodegenerative Diseases
Predictors of levo-dopa induced dyskinesias in Parkinson's disease
PaulJ Alapatt, RT Athulya, S Jayakrishnan, Thomas Iype, Reeja Rajan · 2019 · Annals of Indian Academy of Neurology
Clinical long-term nocturnal sleeping disturbances and excessive daytime sleepiness in Parkinson’s disease
Rocío Del Pino, Ane Murueta‐Goyena, Unai Ayala, Marian Acera, Mónica Fernández, Beatriz Tijero, Mar Carmona, Tamara Fernández, Iñigo Gabilondo, Juan Carlos Gómez‐Esteban · 2021 · PLoS ONE
Family Caregiver Comorbidities in Lewy Body Dementia Versus Alzheimer Disease and Associated Disorders
Jori Erin Fleisher, Anna Moshkovich, Melissa E. Levin, Faizan Akram, Serena Hess, Madhuvanthi Suresh, Cintra D. Bentley, Thomas J. Manak, Maraline Mattke, Allegra Miller et al. · 2022 · Alzheimer Disease & Associated Disorders
Neuropsychology, neuroimaging or motor phenotype in diagnosis of Parkinson’s disease-dementia: which matters most?
Francesca Di Biasio, Nicola Vanacore, Alfonso A. Fasano, Nicola Modugno, Barbara Gandolfi, Francesco Lena, Giovanni Grillea, Sara Pietracupa, Giovanni Caranci, Stefano A. Ruggieri · 2011 · Journal of Neural Transmission
Pharmacogenetics of Antipsychotic-Induced Movement Disorders as a Resource for Better Understanding Parkinson’s Disease Modifier Genes
Lior Greenbaum, Bernard Lerer · 2015 · Frontiers in Neurology
Economic Evaluation of Ropinirole Prolonged Release for Treatment of Parkinson’s Disease in The Netherlands
Job F. M. van Boven, Annoesjka Novák, Maurice T. Driessen, Cornelis Boersma, Maarten M. Boomsma, Maarten Jacobus Postma · 2014 · Drugs & Aging
The mGlu2/3 antagonist LY-341,495 reverses the anti-dyskinetic and anti-psychotic effects of the mGlu2 activators LY-487,379 and LY-354,740 in the MPTP-lesioned marmoset
Stephen G. Nuara, Adjia Hamadjida, Jim C. Gourdon, Philippe Huot · 2020 · Journal of Neural Transmission
New Developments in Cholinergic Imaging in Alzheimer and Lewy Body Disorders
Chesney Elizabeth Craig, Nicola J. Ray, Martijn L.T.M. Müller, Nicolaas Ida Bohnen · 2020 · Current Behavioral Neuroscience Reports
Empowering Melatonin Therapeutics with Drosophila Models
Cassandra Millet-Boureima, Caroline C. Ennis, Jurnee Jamison, Shana McSweeney, Anna Park, Chiara Gamberi · 2021 · Diseases
Interplay between gait and neuropsychiatric symptoms in Parkinson’s Disease
Michela Russo, Marianna Amboni, Antonio Volzone, Gianluca Ricciardelli, Giuseppe Cesarelli, Alfonso Maria Ponsiglione, Paolo Barone, Maria Romano, Carlo Ricciardi · 2022 · European Journal of Translational Myology
Rivastigmine for the treatment of dementia associated with Parkinson’s disease
John C. Morgan · 2008 · Neuropsychiatric Disease and Treatment
L-DOPA-induced dyskinesia, is striatal dopamine depletion a requisite?
Philippe Huot · 2015 · Journal of the Neurological Sciences
Nondopaminergic Treatments for Parkinson’s Disease
Philippe Huot, Susan Helen Fox · 2011 · Neurodegenerative Disease Management
A Prospective Evaluation of an Outpatient Assessment of Postural Instability to Predict Risk of Falls in Patients with Parkinson's Disease Presenting for Deep Brain Stimulation
Nicholas James Brandmeir, Cheryl L. Brandmeir, Kristine Kuzma, James McInerney · 2015 · Movement Disorders Clinical Practice
Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases
Christian Hölscher · 2020 · International review of neurobiology
Behavioural interventions for swallowing in subjects with Parkinson's disease: A mixed methods systematic review
Katharina Winiker, Berit Kertscher · 2023 · International Journal of Language & Communication Disorders
Complex Exercises Improve Cognition in People With Parkinson’s Disease and Freezing of Gait
Carla Silva‐Batista, Filipe Oliveira de Almeida, Alana Xavier Batista, Egberto Reis Barbosa, Fay Bahling Horak, Carlos Ugrinowitsch · 2024 · Neurorehabilitation and neural repair
Emerging drugs for levodopa-induced dyskinesia
Amaal AlDakheel, Isabelle Beaulieu‐Boire, Susan Helen Fox · 2014 · Expert Opinion on Emerging Drugs
Palliative Care and Nonmotor Symptoms in Parkinson's Disease and Parkinsonism
Nataliya Titova, К. Ray Chaudhuri · 2017 · International review of neurobiology
Quality of life and resource utilization‐Swedish data from the Care of Late‐Stage Parkinsonism (CLaSP) study
Jenny M. Norlin, Frida Hjalte, Christopher Kruse, Richard C. Dodel, Kristina Rosqvist, Per Odin · 2022 · Acta Neurologica Scandinavica
The mGluR2/3 orthosteric agonist LY-404,039 reduces dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset
Woojin Kang, Stephen G. Nuara, Dominique Bédard, Imane Frouni, Cynthia Kwan, Adjia Hamadjida, Jim C. Gourdon, Fleur Gaudette, Francis Beaudry, Philippe Huot · 2023 · Naunyn-Schmiedeberg s Archives of Pharmacology
Long-term follow-up of subthalamic nucleus deep brain stimulation in patients with Parkinson's disease: An analysis of survival and disability milestones
Raquel Pinheiro Barbosa, Leonor Correia Guedes, Maria Begoña Cattoni, Patrícia Pita Lobo, Ana Castro Caldas, Margherita Fabbri, Paulo André Dias Bastos, Anabela Valadas, Herculano Carvalho, Luísa Albuquerque et al. · 2023 · Parkinsonism & Related Disorders
5-HT4R agonism reduces L-DOPA-induced dyskinesia via striatopallidal neurons in unilaterally 6-OHDA lesioned mice
Demetra Ballardin, Leila Makrini, Alexander Seper, Emmanuel Valjent, Heike Rebholz · 2024 · Neurobiology of Disease
Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing
Brandon R. Barton, Bryan A. Bernard, Virginie Czernecki, Jennifer G. Goldman, Glenn T. Stebbins, Bruno Dubois, Christopher G. Goetz · 2014 · Movement Disorders
The Health Profile of People Living with Parkinson?s Disease Managed in a Comprehensive Care Setting
Meg E. Morris · 2015 · Journal of Aging Science
Levodopa en el tratamiento de la enfermedad de Parkinson: mitos y realidades
M. R. Luquín, Pedro Ruiz, Marı́a José Martı́, Ana Rojo Sebastián, Lydia Vela, Francisco Grandas, Mariano Bravo-Utrera, Juan Andrés Burguera, José Chacón, Víctor M. Campos Arillo et al. · 2012 · Revista de Neurología
Parkinson's Disease (PD)
Ansgar M. Brambrink, Ines P. Koerner · 2007 · Elsevier eBooks
Reciprocal cross-sensitization of D1 and D3 receptors following pharmacological stimulation in the hemiparkinsonian rat
Kathryn Lanza, Katherine Chemakin, Sarah Lefkowitz, Carolyn Saito, Nicole Chambers, Christopher Bishop · 2019 · Psychopharmacology
Parkinsonism
Stanley Fahn, Joseph J. Jankovic, Mark Hallett · 2011 · Elsevier eBooks
Cognitive Impairment in Parkinson’s Disease: What We Know so Far
Cèlia Painous, Marı́a José Martı́ · 2020 · Research and Reviews in Parkinsonism
Risk of accidental injuries amongst P arkinson disease patients
Hung‐Chen Wang, Cheng‐Chieh Lin, Chi Ieong Lau, A. Chang, Fung Chang Sung, C.‐H. Kao · 2014 · European Journal of Neurology
Adenosine Receptors and Dyskinesia in Pathophysiology
Masahiko Tomiyama · 2014 · International review of neurobiology
Can deep brain stimulation be a therapeutic option for Parkinson's disease dementia?
Han‐Joon Kim, Beomseok Jeon, Jee‐Young Lee, Sun Ha Paek · 2016 · Neurology and Clinical Neuroscience
Hallucinogenic mechanisms: pathological and pharmacological insights
Simon J.G. Lewis, James M. Shine, Daniel Brooks, Glenda Margaret Halliday · 2014 · Wiley eBooks
5-HT 2A Receptors and Parkinson’s Disease Psychosis: A Pharmacological Discussion
Philippe Huot · 2018 · Neurodegenerative Disease Management
Approaches for treating neuropsychiatric symptoms in Parkinson’s disease: a narrative review
Jon Rodríguez-Antigüedad, Gonzalo Olmedo‐Saura, Javier Pagonabarraga, Saül Martínez‐Horta, Jaime Kulisevsky · 2025 · Therapeutic Advances in Neurological Disorders
Successful Treatment of Levodopa/Carbidopa Intestinal Gel Associated “Biphasic‐like” Dyskinesia with Pallidal Deep Brain Stimulation
Eoin Mulroy, Valentina Leta, Ludvic U. Zrinzo, Thomas Foltynie, К. Ray Chaudhuri, Patricia Dowsey Limousin · 2020 · Movement Disorders Clinical Practice
Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease
Natalie Lipari, Ashley Centner, John Glinski, Sophie R. Cohen, Fredric P. Manfredsson, Christopher Bishop · 2022 · Neurobiology of Disease
Real-world evidence on levodopa dose escalation in patients with Parkinson’s disease treated with istradefylline
Nobutaka Hattori, Daijiro Kabata, Shinji Asada, Tomoyuki Kanda, Takanobu Nomura, Ayumi Shintani, Akihisa Mori · 2023 · PLoS ONE
A novel wearable laser device to regulate stride length in Parkinson's disease
Yan Zhao, Stefan Ramesberger, Urban M. Fietzek, Lorenzo D’Angelo, Tim Christian Lueth · 2013 · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)
Antiparkinsonian Effects of a Metabotropic Glutamate Receptor 4 Agonist in MPTP-Treated Marmosets
Elizabeth H. Mann, Michael Jackson, Louise Lincoln, Ria Fisher, Sarah Rose, Susan Duty · 2020 · Journal of Parkinson s Disease
The correlation of non-motor symptoms and sleep on balance in Parkinson’s disease patients with normal cognition and mild cognitive impairment
Mevhibe Sarıcaoğlu, Nesrin Helvacı Yılmaz, Fahriye Feriha Özer, Lütfü Hanoğlu · 2021 · Irish Journal of Medical Science (1971 -)
Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease ‘OFF’ episodes
Andrew Thach, Miriam L. Zichlin, Noam Y. Kirson, Karen Yang, Katherine Gaburo, Eric J. Pappert, Darshan A. Mehta, G. Rhys Williams · 2022 · Journal of Comparative Effectiveness Research
Non-Motor Symptoms in Parkinson's Disease
Bilal El‐Mansoury, Abdelali Ben Maloui, Ahmed Draoui, Youssef Ait Hamdan, Mjid Oukhrib, Kamal Smimih, Abdessamad Elmourid, Abdelaati El Khiat, Samira Boulbaroud, Iman Meftah et al. · 2023 · Advances in medical diagnosis, treatment, and care (AMDTC) book series
Ageism in Studies of Rehabilitation in Parkinson's Disease
Mary Buckley, Desmond J O’Neill · 2015 · Journal of the American Geriatrics Society
Rehabilitative therapy in patients with Parkinson's disease
Georg Ebersbach · 2014 · Basal Ganglia
Effects of Chinese herbal medicine Bushen Huoxue Granule on quality of life of patients with Parkinson disease: a randomized, double-blinded and placebo-controlled trial
Min Li · 2012 · Journal of Chinese Integrative Medicine
A Simple Question About Falls to Distinguish Balance and Gait Difficulties in Parkinson's Disease
ABRAHAM N. LIEBERMAN, Narayanan Krishnamurthi, Rohit Dhall, Anthony Santiago, Guillermo Moguel‐Cobos, Arshia Sadreddin, Sameea Husain, Naomi Salins, Di Pan · 2012 · International Journal of Neuroscience
Challenges of multidisciplinary care in Parkinson's disease
Sotirios Andreas Parashos · 2013 · The Lancet Neurology
Nonmotor Disorders and Their Correlation With Dopamine
Juan Carlos Martínez‐Castrillo, Lydia Vela, Javier del Val, Araceli Alonso Cánovas · 2011 · The Neurologist
Lung Function Testing On and Off Dopaminergic Medication in Parkinson's Disease Patients With and Without Dysphagia
Tareq G. Sawan, M. LOU HARRIS, Christopher Kobylecki, Laura W. J. Baijens, Michel R. A. van Hooren, Emilia Michou · 2015 · Movement Disorders Clinical Practice
A Cross‐Sectional Comprehensive Assessment of the Profile and Burden of Non‐motor Symptoms in Relation to Motor Phenotype in the Nigeria Parkinson Disease Registry Cohort
Oluwadamilola Omolara Ojo, Kolawole Wahab, Abiodun Hamzat Bello, Sani A. Abubakar, Bertha C. Ekeh, Folajimi Morenikeji Otubogun, Emmanuel Uzodinma Iwuozo, Temitope Farombi, Olaleye Akinmola Adeniji, Francis Ibe Ojini et al. · 2021 · Movement Disorders Clinical Practice
Levodopa-induced Dyskinesia: A Brief Review of the Ongoing Clinical Trials
Philippe Huot, Woojin Kang, Esther Kim, Dominique Bédard, Sébastien Belliveau, Imane Frouni, Cynthia Kwan · 2021 · Neurodegenerative Disease Management
Cognitive Deficits in Parkinson’s Disease
Eliana Roldán Gerschcovich, Kuei Yuan Tseng · 2008 · Humana Press eBooks
Cognitive changes in Parkinson's disease during subthalamic stimulation: a clinicopathologic study
Francesc Valldeoriola · 2006 · Journal of Neurology Neurosurgery & Psychiatry
Communication gaps about OFF periods between physicians and patients with Parkinson’s disease: a patient–physician dialogue analysis
Anna V Levit, Cheryl Zebendon, Lauren A. Walter, Patricia O’Donnell, Connie Marras · 2019 · Research and Reviews in Parkinsonism
Advanced Parkinson’s disease treatment patterns in Italy: an observational study interim analysis
Fabrizio Stocchi, Paolo Barone, Roberto Ceravolo, Maria Francesca De Pandis, Leonardo Lopiano, Nicola Modugno, Alessandro Padovani, Manuela Pilleri, Alessandro Tessitore, Mario Zappia · 2024 · Annals of Medicine
Knowledge mapping and research trends of accidental falls in patients with Parkinson’s disease from 2003 to 2023: a bibliometric analysis
Luya Shi, Bongsook Yih · 2024 · Frontiers in Neurology
Neuroinflammation and Dyskinesia: A Possible Causative Relationship?
Antonella Cardinale, Antonio de Iure, Barbara Picconi · 2024 · Brain Sciences
Effects of sensory substituted functional training on balance, gait, and functional performance in neurological patient populations: A systematic review and meta-analysis
Peter Lynch, Kenneth Monaghan · 2021 · Heliyon
Non-motor symptoms in Thai patients with Parkinson's disease studied at Phramongkutklao Hospital.
Kiratikorn Vongvaivanich, Samart Nidhinandana, Chesda Udommongkol, Pamsiri Chairungsaris, Yotin Chinvarun, Wanna Wongmek, Seema Suphakasem, Jithanorm Suwantamee, Pasiri Sithinamsuwan · 2014 · PubMed
Long-term Parkinson's disease – Time for optimism
Shlomit Yust‐Katz, Sonia Sthneer, Eldad Melamed, Ruth Djaldetti · 2008 · Biomedicine & Pharmacotherapy
Mortality in Parkinson's disease is not associated with the severity of early dopaminergic defect
Juha T. Järvelä, Juha O. Rinne, Olli Eskola, Valtteri Kaasinen · 2014 · Parkinsonism & Related Disorders
Factors contributing to postural instability in patients with idiopathic Parkinson’s disease
Kareem S. Diab, Leigh Anne Hale, Debra Lynn Waters, Margot A. Skinner · 2014 · Physical Therapy Reviews
Reaching Those Most in Need – A Call to Action for Advanced Parkinson’s Disease
Shashank Agarwal, Jori Erin Fleisher · 2016 · European Neurological Review
NLX-112, a highly selective 5-HT1A receptor agonist: Effects on body temperature and plasma corticosterone levels in rats
Adrian Newman‐Tancredi, Ronan Depoortère, Elisabeth Carilla-Durand, Jean Pierre Tarayre, Mark S. Kleven, Wouter Koek, Laurent Bardin, Mark A. Varney · 2017 · Pharmacology Biochemistry and Behavior
Illness Representations and Coping Strategies in Patients Treated with Deep Brain Stimulation for Parkinson’s Disease
Marc Baertschi, Nicolas Favez, João Flores Alves Dos Santos, Michalina Radomska, François Richard Herrmann, Pierre R. Burkhard, Alessandra Canuto, Kerstin Weber, Paolo Ghisletta · 2020 · Journal of Clinical Medicine
Falls risk is predictive of dysphagia in Parkinson’s disease
Christopher Kobylecki, Irena Shiderova, Marciana Ionela Boca, Emilia Michou · 2021 · Neurological Sciences
Towards quantifying the impact of Parkinson's disease using GPS and lifespace assessment
David Ireland, Simon J. McBride, Jacki Liddle, Helen J. Chenery · 2013 · International Conference on Biomedical Engineering and Informatics (BMEI)
Pharmacotherapy in Parkinson’s disease: case studies
Tiago Mestre, Joaquim José Ferreira · 2010 · Therapeutic Advances in Neurological Disorders
Targeting Ferroptosis in Parkinson’s: Repurposing Diabetes Drugs as a Promising Treatment
Carmen Duţă, Corina Muscurel, Carmen Beatrice Dogaru, Irina Anna-Maria Stoian · 2025 · International Journal of Molecular Sciences
Let Us Talk Money: Subjectively Reported Financial Performance of People Living with Neurodegenerative Diseases—A Systematic Review
Akke‐Marij D. Ariesen, Roosa E. Tuomainen, Peter Paul De Deyn, Oliver M. Tucha, Janneke Koerts · 2023 · Neuropsychology Review
Factors affecting progression of non-Alzheimer dementia: a retrospective analysis with long-term follow-up
Reza Ghouri, Nevra Öksüz, Bahar Taşdelen, Aynur Özge · 2023 · Frontiers in Neurology
An Examination of Cognitive Heterogeneity in Parkinson Disease: The Dual-Syndrome Hypothesis
Dale Summers, Kristie A. Spencer, Connie Okasaki, Jessica E. Huber · 2024 · Journal of Speech Language and Hearing Research
Is there room for new non-dopaminergic treatments in Parkinson’s disease?
Manuela Pilleri, Konstantinos Koutsikos, Angelo Antonini · 2012 · Journal of Neural Transmission
Seniors with Parkinson's Disease: Initial Medical Treatment
J. Eric Ahlskog · 2010 · Journal of Clinical Neurology
Statistical Models of Parkinson’s Disease Progression: Predictive Validity in a 3-Year Follow-up
Alexandre Mendes, Alexandra Gonçalves, Nuno Vila‐Chã, Margarida Calejo, Ines C. Moreira, Joana Fernandes, Joana Damásio, Armando M Teixeira-Pinto, Paul Krack, António Bastos Lima et al. · 2016 · Journal of Parkinson s Disease